|
Nov 4
|
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
|
|
Oct 22
|
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
|
|
Oct 19
|
China Arrests Japanese Executive Despite Tokyo’s Appeals
|
|
Aug 25
|
Astellas Joins Record Bond Sales by Japan Inc. With M&A Debt
|
|
Aug 23
|
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
|
|
Aug 21
|
Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
|
|
Aug 21
|
New Strong Sell Stocks for August 21st
|